LeMaitre Vascular’s top executives continue to offload shares as the stock reaches its highest point in a year—Here’s why savvy investors are cashing out at this moment

Insider Activity: Beyond the Headlines

While news stories often grab attention, savvy investors are digging into the details behind the numbers. In the case of LeMaitre Vascular, a recent insider transaction by Senior VP Trent G. Kamke offers more insight than it might first appear. On March 11, Kamke exercised and immediately sold 2,625 shares, netting approximately $285,000. This move aligns with a typical liquidity event, where executives sell shares acquired through vested options to manage their personal finances after receiving a significant equity award.

However, a closer look reveals a deliberate and consistent approach. The sale accounted for 28.22% of Kamke's direct holdings prior to the transaction, mirroring the median percentage he has sold in each transaction since December. Importantly, he still holds 1,353 stock options, indicating continued investment in the company's future. Rather than a sign of panic, these sales appear to be part of a planned strategy to gradually realize gains.

The timing of the sale is also noteworthy. Kamke sold following a strong post-earnings rally, as the stock climbed on the back of improved margins and optimistic guidance. In this context, locking in profits from vested options seems like a prudent, risk-managed decision rather than a lack of faith in the business. It highlights a common dynamic: even those with a long-term stake may choose to take some profits when the stock appears to have reached a short-term high.

Ultimately, this transaction fits the mold of a standard liquidity event. Yet, in a market where insider selling is prevalent, even routine sales contribute to a broader narrative. The real alignment of interests often comes from insiders who continue to hold their options, rather than those who cash out at the first opportunity. For now, Kamke's sale is a reminder that the most patient investors may reap the greatest rewards.

Insider Trends: Holding vs. Selling

Examining the bigger picture, insider activity at LeMaitre Vascular reveals a clear trend. Over the past year, insiders have sold a combined $18.7 million worth of shares, with no insider purchases reported. CEO George W. Lemaitre has led the way, accounting for the majority of these sales, including a single 100,000-share transaction in August 2025 that brought in over $9.3 million. In total, he has sold more than $18 million in the last twelve months, underscoring a significant shift in insider ownership.

These sales are not isolated events. Four insiders—including the CEO and three directors—have reduced their stakes, signaling a notable outflow of capital from the executive team. Meanwhile, the company's institutional ownership paints a different picture. While 604 institutions currently hold shares, most are passive investors like BlackRock and Vanguard, who are maintaining their positions rather than increasing them. Their filings show no signs of active accumulation.

The contrast is striking: insiders are consistently selling, while large institutional holders are simply holding steady. This divergence raises questions about insider confidence in the company's near-term prospects. When those with the most intimate knowledge of the business are locking in gains, it can serve as a cautionary signal for other investors. True long-term alignment is often found in those who retain their options and wait for future growth, rather than those who exit at market highs.

Strategy Backtest: ATR Volatility Breakout (Long Only)

• Strategy Overview: This approach enters trades when the 14-day ATR exceeds its 60-day simple moving average and the price closes above the 20-day high. Exits occur if the price closes below the 20-day low, after 20 trading days, or if a take-profit of +8% or stop-loss of −4% is triggered. The backtest covers the period from March 28, 2024, to March 27, 2026.

• Key Results:
• Strategy Return: -16.53%
• Annualized Return: -8.14%
• Maximum Drawdown: 28.43%
• Profit-Loss Ratio: 0.8
• Total Trades: 6 (2 winners, 4 losers)
• Win Rate: 33.33%
• Average Hold: 9.33 days
• Average Win: 5.81%
• Average Loss: 6.92%
• Largest Gain: 8.2%
• Largest Loss: 14.23%

This data suggests that recent insider selling is part of a broader pattern, not just isolated events. The significant volume of sales by multiple executives stands in contrast to the passive stance of institutional investors, who are not actively increasing their positions.

Financial Performance: Growth Meets High Valuation

LeMaitre Vascular is delivering strong operational results. Management forecasts 12% sales growth and 22% adjusted earnings growth for the current year, supported by a recent 16% increase in quarterly sales and an upward revision to full-year guidance. This robust performance has fueled a rally in the stock price.

The stock has surged nearly 31% year-to-date and is up more than 21% over the past 120 days, trading close to its 52-week high. However, volatility has also increased, with a 120-day volatility of 5.94%, indicating that the stock is reacting more to news and sentiment than to steady fundamentals.

Despite the impressive growth, the valuation is demanding. The forward price-to-earnings ratio is close to 49, and the price-to-sales ratio exceeds 9.7—levels that suggest the market is expecting near-flawless execution. With insiders selling into this strength, it appears they believe much of the growth story is already reflected in the current price, or that the stock may be peaking.

The takeaway is clear: while the company's financials are strong, the stock's rapid ascent may have outpaced even its impressive growth. Investors must decide whether the premium valuation is justified by future earnings, or if the recent rally has already captured most of the upside. The pattern of insider selling, combined with lofty multiples, serves as a caution that the easy gains may be behind us.

Key Catalysts and Risks for Investors

For those following the smart money, the next moves are crucial. The pattern of insider selling is established, but future data will determine whether this trend continues or reverses. Investors should keep a close eye on three main areas:

• Institutional Holdings: Watch for updates in 13F filings, especially from major passive funds like BlackRock and Vanguard. While 604 institutions currently hold shares, there is no sign of active accumulation. Any reduction in their holdings in the upcoming reports could signal waning confidence from large investors.
• Earnings Reports: The company's projections of 12% sales growth and 22% earnings growth set a high bar. Any shortfall, particularly on the earnings front, could quickly change the market's bullish outlook and lead to a sharp correction, given the stock's premium valuation.
• Insider Transactions: Another significant sale by the CEO or other top executives would reinforce the trend of insiders cashing out. With the CEO already having sold over $18 million in the past year, a new large transaction would be a strong bearish signal.

In summary, the smart money is waiting for the next catalyst—be it a shift in institutional sentiment, a surprise in earnings, or another major insider sale—to confirm whether the current rally can be sustained or if a reversal is on the horizon. In a market already running hot, these signals will be critical for investors navigating the next phase.